Clinical trials: Cavernous Malformations
Cavernous Malformations,Cerebral and/or Spinal
Oral Propanolol for Surgically Inaccessible Cavernous Malformations
The purpose of this study is to evaluate the role of propranolol as an alternative treatment for cavernous malformation in patients that may not be ideal candidates for surgery.
- Trial name
- NCT03523650
- Testing
- Propranolol Oral Tablet
- Where
- United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
CCM Blood Biomarker Validation Study
Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke.
- Trial name
- NCT05148663
- Testing
- CCM Hemorrhagic Panel
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Cerebral Cavernous Malformations
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers).
- Trial name
- TOUCH (NCT03467295)
- Testing
- Surgery, Observation
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Hemangioma, Cavernous, Central Nervous System
Study on Treatment Decision-Making and Prognostic Follow-Up for Untreated Cerebral Cavernous Malformations
The goal of this observational study is to evaluate and predict the risk associated with cerebral cavernous malformations (CCMs) using advanced artificial intelligence and radiomics analysis technology.
- Trial name
- NCT06214767
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Tiantan Hospital
Arteriovenous Malformations, Cavernous Angiomas
Influence of MMP on Brain AVM Hemorrhage
Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology and pathogenesis are unknown.
- Conditions
- Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
- Trial name
- NCT00783523
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Cavernous Angioma, Familial, Cerebral Cavernous Malformations
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches.
- Conditions
- Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
- Trial name
- NCT01764529
- Where
- 7 sites in United States
- Volunteers
- 789 people
- Sponsor
- University of California, San Francisco
Carotid-Cavernous Sinus Fistula
Endovascular Management of Direct Carotid-cavernous Fistula
Carotid-cavernous fistula (CCF) refers to an aberrant arteriovenous communication between the carotid arterial system and the venous compartments of the cavernous sinus (CS) Direct CCFs are when there is a direct fistulous…
- Trial name
- NCT06091150
- Testing
- Endovascular management of direct carotid-cavernous fistula
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Sohag University
Lymphatic Malformations
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
- Trial name
- EPIK-L1 (NCT05948943)
- Testing
- Alpelisib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
CCM, Familial Cerebral Cavernous Malformation
Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study
Patients with symptomatic and asymptomatic familial cerebral cavernous malformation (fCCM) will be included. The goal of this observational study is to learn about the long-term evolution of this condition.
- Trial name
- CCM_Italia (NCT06983132)
- Testing
- Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading, Determination of circulating biomarkers
- Where
- 6 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico